Payment overview · 2025
General Payments
$72.71
3 reported records · 3 companies
Healthcare provider profile · identity verified
Mark C Hudson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CAIRO, GA · NPI 1437112497
Verified facts
What the public records show
CMS Open Payments records show Mark C Hudson, D.O. received $72.71 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 47.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.62 | 47.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.77 | 28.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.32 | 23.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.71 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $34.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
168 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
44 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
269 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 176 |
| Famotidine | Famotidine | 757 | 158 |
| Losartan Potassium | Losartan Potassium | 535 | 116 |
| Gabapentin | Gabapentin | 489 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 83 |
| Montelukast Sodium | Montelukast Sodium | 374 | 81 |
| Carvedilol | Carvedilol | 363 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 75 |
| Furosemide | Furosemide | 302 | 68 |
| Metformin Hcl | Metformin Hcl | 280 | 64 |
| Eliquis | Apixaban | 269 | 51 |
| Allopurinol | Allopurinol | 230 | 46 |
| Jardiance | Empagliflozin | 225 | 37 |
| Lisinopril | Lisinopril | 220 | 50 |
| Nifedipine Er | Nifedipine | 219 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 52 |
| Ozempic | Semaglutide | 168 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 26 |
| Potassium Chloride | Potassium Chloride | 146 | 30 |
| Tramadol Hcl | Tramadol Hcl | 144 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 25 |
| Meloxicam | Meloxicam | 132 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 25 |
| Celecoxib | Celecoxib | 119 | 30 |
| Farxiga | Dapagliflozin Propanediol | 115 | 23 |
| Spironolactone | Spironolactone | 114 | 21 |
| Trulicity | Dulaglutide | 111 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 31 |
| Alendronate Sodium | Alendronate Sodium | 103 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 16 |
| Chlorthalidone | Chlorthalidone | 96 | 23 |
| Atenolol | Atenolol | 86 | 13 |
| Doxepin Hcl | Doxepin Hcl | 84 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 19 |
| Sertraline Hcl | Sertraline Hcl | 77 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 14 |
| Januvia | Sitagliptin Phosphate | 72 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 19 |
| Clonazepam | Clonazepam | 71 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 12 |
| Mirtazapine | Mirtazapine | 69 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 66 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 23 |
| Topiramate | Topiramate | 66 | 12 |
| Trazodone Hcl | Trazodone Hcl | 66 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 15 |
| Donepezil Hcl | Donepezil Hcl | 61 | suppressed |
| Pregabalin | Pregabalin | 61 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 13 |
| Mupirocin | Mupirocin | 56 | 25 |
| Omeprazole | Omeprazole | 56 | 23 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Simvastatin | Simvastatin | 52 | 13 |
| Glimepiride | Glimepiride | 50 | 13 |
| Entresto | Sacubitril/Valsartan | 49 | 13 |
| Finasteride | Finasteride | 48 | 13 |
| Baclofen | Baclofen | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 36 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 44 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Prednisone | Prednisone | 40 | 26 |
| Dexamethasone | Dexamethasone | 38 | 26 |
| Linzess | Linaclotide | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 11 |
| Valsartan | Valsartan | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Eplerenone | Eplerenone | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Novolog | Insulin Aspart | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72.71 · 3 records | PFIZER INC. | QULIPTA, UBRELVY, VYNDAQEL, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error